Experts begin their panel discussion on OAB by describing the typical diagnostic process and initial conversations that they have with patients suspected of having the condition.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Digital health treatment program found safe, effective for urinary incontinence
July 10th 2024"We believe the collective findings are unique in urogynecology and offer strong evidence that first-line incontinence treatment is effective, and women can access it using the Leva System,” says Evelyn Hall, MD.